Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Survival Tree01:19

Survival Tree

210
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
210
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

384
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
384
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

234
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
234
Cancer Survival Analysis01:21

Cancer Survival Analysis

504
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
504
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

375
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
375
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

793
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
793

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative learning of individualized treatment rules from multiple studies with partially overlapping treatments.

Biometrics·2026
Same author

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Information-Based Composite Likelihood Method for Hybrid Meta-Analysis Integrating Individual Participant Data and Aggregated Data.

Statistics in medicine·2026
Same author

SEMIPARAMETRIC ANALYSIS OF INTERVAL-CENSORED DATA SUBJECT TO INACCURATE DIAGNOSES WITH A TERMINAL EVENT.

The annals of applied statistics·2026
Same author

DYNAMIC CLASSIFICATION OF LATENT DISEASE PROGRESSION WITH AUXILIARY SURROGATE LABELS.

The annals of applied statistics·2026
Same author

Asymptotic Inference for Multi-Stage Stationary Treatment Policy with Variable Selection.

Journal of machine learning research : JMLR·2026

Related Experiment Video

Updated: Nov 10, 2025

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

1.5K

Inferring latent heterogeneity using many feature variables supervised by survival outcome.

Beilin Jia1, Donglin Zeng1, Jason J Z Liao2

  • 1Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Statistics in Medicine
|April 5, 2021
PubMed
Summary
This summary is machine-generated.

This study introduces a novel mixture model to identify patient subgroups in cancer, enabling precision medicine by pinpointing high-risk individuals using biomarkers and survival data.

Keywords:
adaptive lassocensoringlatent modelmixture distributionoracle property

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K

Related Experiment Videos

Last Updated: Nov 10, 2025

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

1.5K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K

Area of Science:

  • Biostatistics
  • Computational Biology
  • Oncology

Background:

  • Understanding cancer patient heterogeneity is crucial for effective precision medicine.
  • Identifying latent patient subgroups can guide targeted therapies for high-risk individuals.

Purpose of the Study:

  • To develop a statistical model for inferring latent heterogeneity in cancer patient survival.
  • To incorporate variable selection for identifying key features characterizing these subgroups.

Main Methods:

  • A mixture model approach is proposed to capture distinct patient survival patterns.
  • Multinomial distribution models mixing probabilities for latent groups.
  • Adaptive lasso is integrated for parsimonious variable selection.

Main Results:

  • The proposed adaptive lasso estimator demonstrates oracle properties.
  • Simulation studies validate the finite sample performance of the method.
  • The model is successfully applied to two real-world cancer datasets.

Conclusions:

  • The developed mixture model effectively identifies latent patient heterogeneity in cancer.
  • Variable selection enhances the interpretability and applicability of the model for precision oncology.
  • This approach aids in timely and precise targeting of high-risk cancer patients.